Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 90.10% | -10.49% | 72.63% | 50.41% | -14.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.13% | -43.71% | 57.77% | -21.43% | -20.61% |
| Operating Income | -11.13% | 18.69% | -57.77% | 21.43% | 20.61% |
| Income Before Tax | 673.47% | 800.48% | 200.14% | 421.20% | 21.18% |
| Income Tax Expenses | 18,696.03% | 1,805.82% | -150.96% | 876.35% | -107.71% |
| Earnings from Continuing Operations | 489.41% | 601.31% | 198.14% | 346.35% | 44.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -73.91% | 250.00% |
| Net Income | 488.17% | 601.31% | 198.23% | 346.67% | 44.25% |
| EBIT | -11.13% | 18.69% | -57.77% | 21.43% | 20.61% |
| EBITDA | -11.22% | 18.81% | -58.31% | 21.11% | 20.19% |
| EPS Basic | 498.30% | 606.80% | 189.96% | 341.61% | 41.53% |
| Normalized Basic EPS | -39.73% | 227.51% | -176.69% | 22.95% | 32.93% |
| EPS Diluted | 493.55% | 578.95% | 186.37% | 335.42% | 40.91% |
| Normalized Diluted EPS | -37.73% | 223.81% | -176.69% | 25.00% | 33.13% |
| Average Basic Shares Outstanding | -1.68% | -1.10% | 0.36% | 2.10% | 1.91% |
| Average Diluted Shares Outstanding | -0.25% | 1.80% | 0.36% | 4.59% | 2.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |